Oil Prices Climb as Iran Reviews U.S. Peace Proposal Amid Middle East Tensions 
Reflection AI Eyes $25 Billion Valuation in Massive $2.5 Billion Funding Round 
Bank of Japan Officials Signal Continued Interest Rate Hikes Amid Inflation Concerns 
Rio Tinto's Resolution Copper Mine: U.S. Smelting Challenges and Global Operations Update 
Delivery Hero Sells Taiwan Foodpanda to Grab for $600 Million in Debt-Reduction Push 
OpenAI Pulls the Plug on Sora, Ending $1 Billion Disney Partnership 
ECB Eyes Rate Hike Amid Iran Conflict-Driven Energy Price Surge 
Google's TurboQuant Algorithm Sends Memory Chip Stocks Tumbling 
SLMG Beverages Eyes Price Hikes Amid Rising Packaging Costs and India's Booming Soft Drink Market 
9 Tips for Avoiding Tax Season Cyber Scams 
Federal Reserve Balance Sheet Reduction: Brookings Research Outlines Possible Path Forward 
Explosion and Fire Erupt at Valero Oil Refinery in Port Arthur, Texas 
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets 
Time to buy local: war fuel price shocks reveal the folly of a long food supply chain 
Merck's $6 Billion Bid for Terns Pharma Signals Bold Oncology Push 
Wall Street Slides as Iran War Uncertainty, Oil Surge, and AI Fears Rattle Markets 
Australia's Inflation Eases in February but Core Pressures Persist 
Hyundai Pharmaceutical revealed on Tuesday, July 6, that it has submitted an application so it can start selling its abortion pill in South Korea. The company filed for authorization to market at the Ministry of Food and Drug Safety.
Hyundai Pharm is intending to start selling its Mifegymiso that is composed of four tablets of misoprostol and one tablet of mifepristone. Mifepristone is being sold in Korea under the brand name Mifegyne.
First legal abortion pill in S. Korea
According to The Korea Herald, if the ministry will give a go signal for the sale of Mifegymiso, it would effectively become the very first abortion pill that will be legally marketed in the country. In 2019, the Constitutional Court reversed the ban on abortion in the first 14 weeks of pregnancy, so this paved the way for the pills to be produced.
Hyundai Pharm will be distributing Mifegymiso to the market as a prescription drug. This means that only patients with proper medical advice from health professionals will be able to obtain the drug. Without the supervision of a certified health advisor, an individual will not be allowed to purchase the abortion pill.
The U.S. Food and Drug Administration stated that abortion pills are safe to use in the first nine or 10 weeks of pregnancy. While it seems that more and more groups are supporting and even promoting abortion pills, it was reported that the National Assembly is working on revising the Pharmaceutical Affairs Act so it can bar the advertising of the drug.
The marketing license for Mifegymiso
Korea Biomedical Review reported that Hyundai Pharm’s filing for approval for the abortion drug has gained attention because the Ministry of Health and Welfare already granted repayment for doctor’s education and counseling sessions about medical abortion.
The policy asks doctors to give educational counseling to pregnant women regarding abortion. They are allowed to explain the procedures for abortion, including precautions before and after the surgery. The physicians will also be taught about the physical and mental complications of abortion and contraception.
Meanwhile, Hyundai Pharm stated it will do its best to gain approval. “We will closely work with the drug developer to accelerate the regulatory nod for the drug,” a company official said.
